Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.69 |
| ▸ | PLK4 | O00444 | 2/20 | 0.69 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.69 |
| ▸ | ABL1 | P00519 | 2/20 | 0.69 |
| ▸ | EGFR | P00533 | 2/20 | 0.69 |
| ▸ | LCK | P06239 | 2/20 | 0.69 |
| ▸ | FYN | P06241 | 2/20 | 0.69 |
| ▸ | CDK1 | P06493 | 2/20 | 0.69 |
| ▸ | RET | P07949 | 2/20 | 0.69 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.69 |
| ▸ | SRC | P12931 | 2/20 | 0.69 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.69 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.69 |
| ▸ | MARK3 | P27448 | 2/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.69 |
| ▸ | FLT3 | P36888 | 2/20 | 0.69 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.69 |
| ▸ | BTK | Q06187 | 2/20 | 0.69 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.69 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13987799 | 0.86 | AURKA (0.69) | AURKAPLK4CHEK2ABL1EGFR | |
| SCHEMBL14396960 | 0.85 | AURKA (0.75) | AURKAPLK4CHEK2ABL1EGFR | |
| SCHEMBL14502699 | 0.84 | FLT3 (0.67) | AURKAPLK4CHEK2ABL1EGFR | |
| SCHEMBL31517136 | 0.82 | AAK1 (1.00) | AURKAPLK4CHEK2ABL1EGFR | |
| SCHEMBL13987443 | 0.82 | AAK1 (1.00) | AURKAPLK4CHEK2ABL1EGFR | |
| SCHEMBL30278183 | 0.81 | AURKA (0.58) | AURKAPLK4CHEK2ABL1EGFR | |
| SCHEMBL4778208 | 0.80 | AURKA (0.61) | AURKAPLK4CHEK2ABL1EGFR | |
| SCHEMBL13987438 | 0.79 | AURKA (0.67) | AURKAPLK4CHEK2ABL1EGFR | |
| SCHEMBL14503112 | 0.79 | FLT3 (0.66) | AURKAPLK4CHEK2ABL1EGFR | |
| SCHEMBL4815877 | 0.79 | AURKA (0.59) | AURKAPLK4CHEK2ABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163437-B | Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2024123801-A1 | COMPOUNDS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2024-05-30 | — | — | US | disclosed |
| CN-109414442-B | Liquid preparation of compound | 洛克索肿瘤学股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024059010-A1 | COMPOUNDS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3843850-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | ARRAY BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-111630054-B | Substituted pyrazolo [3,4-d ] pyrimidine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-111971286-B | Substituted pyrrolo [2,3-d ] pyrimidine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20230011441-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3906234-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | Array BioPharma Inc. (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-3843850-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | Array BioPharma Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| CN-112930215-A | Pyrazolo [3, 4-b ] pyridine compounds as TAM and MET kinase inhibitors | 阿雷生物药品公司 | 2021-06-08 | — | — | CN | disclosed |
| EP-3753939-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200338079-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2020-10-29 | — | — | US | disclosed |
| WO-2020141470-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2020-07-09 | — | — | WO | disclosed |
| US-20200216416-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200079770-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. | 2020-03-12 | — | — | US | disclosed |
| WO-2020047184-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2019113190-A1 | BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES | ARRAY BIOPHARMA INC. (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011441-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | AURKA 305/4885PLK4 199/4885CHEK2 85/4885 |
| US-20200338079-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | IL5, IL1A, RRP15 | AURKA 1637/4885PLK4 1631/4885CHEK2 1339/4885 |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | AURKA 323/4885PLK4 228/4885CHEK2 96/4885 |
| US-20200079770-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | AURKA 323/4885PLK4 228/4885CHEK2 96/4885 |
| US-20200216416-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MET, MERTK | AURKA 598/4885PLK4 381/4885CHEK2 56/4885 |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | RET, MERTK, MET | AURKA 305/4885PLK4 199/4885CHEK2 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.